surmount-1 trial tirzepatide weight loss non-diabetic SURMOUNT-1: In an RCT, adults with obesity treated with weekly had major over 72 weeks. #ADA2022 https://t.co/X2RrvYxzsV SURMOUNT-1 Trial - Cardionerds Twitter

PMID 16842123

Indications and Usage of Wegovy Wegovy is indicated for chronic weight management in adults with a BMI of 30 or more, or 27 or more with at least one weight-related condition such as hypertension or type 2 diabetes

As the WL achieved with the novel obesity pharmacotherapies approaches that of bariatric surgery, we will need to assess whether long-term complications observed after bariatric surgery such as increased risk of osteoporosis, fractures, macro- and micronutrient deficiencies as well as self-harm behaviours will also be present with pharmacotherapy [112, 113]

Reduces pore size

Immunhistochemical analysis For cFOS analysis, mice were treated s.c

So when you stop taking a GLP-1, food once again moves faster through the stomach, leading to weaker signals to stop eating and potentially increasing food intake